Showing results (31-40 of 115) with videos related to
Sort By:
Pageof 12
Cancer Chemotherapy and Pharmacology|January 1, 1988
Pharmacokinetics of Anandron in patients with advanced carcinoma of the prostateL Pendyala, P J Creaven, R Huben, et al.Cancer Chemotherapy and Pharmacology|January 1, 1997
Effect of glutathione depletion on the cytotoxicity of cisplatin and iproplatin in a human melanoma cell lineL Pendyala, R Perez, A Weinstein, et al.British Journal of Clinical Pharmacology|February 1, 1989
Lack of effect of treatment with human recombinant-tumour necrosis factor (HrTNF) on the binding of quinidine to alpha 1-acid glycoprotein (AGP)J A Barnett, D E Brenner, P J Creaven, et al.Cancer Letters|August 31, 1992
High prevalence of Inoue-Melnick virus antibodies in patients with colorectal carcinomaM Ito, M A Rodriguez-Bigas, P J Creaven, et al.Cancer Chemotherapy and Pharmacology|January 1, 1983
Pharmacokinetics of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum IV (CHIP) in patients with advanced cancerL Pendyala, W Greco, J W Cowens, et al.Cancer|November 1, 1982
Pharmacokinetics of methotrexate following intravenous and intraventricular administration in acute lymphocytic leukemia and non-Hodgkin's lymphomaL J Ettinger, D S Chervinsky, A I Freeman, et al.Cancer Chemotherapy and Pharmacology|January 1, 1995
Intracellular glutathione and cytotoxicity of platinum complexesL Pendyala, P J Creaven, R Perez, et al.Cancer Chemotherapy and Pharmacology|January 1, 1990
DNA binding of iproplatin and its divalent metabolite cis-dichloro-bis-isopropylamine platinum (II)L Pendyala, A V Arakali, P Sansone, et al.Cancer Chemotherapy and Pharmacology|January 1, 1985
Evaluation of the nephrotoxicity of iproplatin (CHIP) in comparison to cisplatin by the measurement of urinary enzymesL Pendyala, S Madajewicz, S B Lele, et al.American Journal of Clinical Oncology|February 1, 1982
Phase II study of 3-deazauridine in advanced colorectal adenocarcinomaS Bruno, P J Creaven, E Ledesma, et al.Pageof 12